Latest / Decera Clinical Education Oncology Podcast
ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:
Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancer
The importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patients
Results from the NATALEE PAM50…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.